Lupin and Avas Launch NaMuscla® in Italy Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January 28, 2025: Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) today announced the launch of Lupin’s orphan drug NaMuscla® (mexiletine) in Italy. Avas will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla® is the first and only licensed product for th...
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders Mumbai, Zug, January 9, 2023: Global pharma major Lupin Limited (Lupin) and Exeltis Healthcare S.L (Exeltis) announced ...
LUPIN: Outlook hinges on niche approvals/cost minimization (LPC IN, Mkt Cap USD3.8b, CMP INR660, TP INR610, 8% Downside, Neutral) The US portfolio rationalization drags profitability for the quarter Lupin (LPC) delivered lower-than-expected 1QFY23 performance, led by a decline in the US sales and reduced operating leverage. EBITDA margin was below its previous lows and stood at 4.4%. We cut our EPS by 35%/3% for FY23E/FY24E factoring in: a) inventory write-down and shelf stock adjustment i...
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories Mumbai, Zug, February 09, 2022: Global pharma major, Lupin Limited (Lupin) announced today that it has entered into a distribution agreement with Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myo...
The general evaluation of LUPIN (IN), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 14, 2021, the closing price was INR 943...
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 4 November 2021: Global pharma major Lupin today announces that the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) recommending the routine funding of Namuscla (mexiletine) in England and Wale...
A director at Lupin Limited sold 20,000 shares at 974.000INR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
LUPIN: FY22 begins on weak note, led by competitive pressures in US (LPC IN, Mkt Cap USD6.4b, CMP INR1050, TP INR1040, 1% Downside, Neutral) Ramp-up in niche products – the key to improving profitability Lupin (LPC) delivered a significant miss on 1QFY22 core earnings, weighed by lower margins in the US segment. This was offset, to some extent, by a milestone payment of USD50m on the clinical progress of the MEK inhibitor from Boehringer Ingelheim. LPC continues to build a complex produc...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 16th February 2021: Lupin is disappointed that the National Institute for Health and Care Excellence (NICE) has published an Appraisal Consultation Document (ACD)1 recommending not to approve NaMuscla (mexiletine) for routine funding to tre...
Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Scottish Medicines Consortium approves NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 8 December 2020: Lupin welcomes the Scottish Medicines Consortium’s (SMC) decision to approve the use of NaMuscla® (mexiletine) for the treatment of symptomatic myotonia in adult patients with non-dystrophic myotonic disorders (NDM) in Scotland.1 NaMuscla is the first licensed med...
US FDA Grants Mexiletine Orphan Drug Designation US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to mexiletine hydrochloride for the treatment of myotonic disorders. Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called myotonia. Myotonia is an inability to relax a contraction of skeletal muscle which originates from a voluntary muscular contraction such as shaking someon...
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla® Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla® Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic disorders in three key territories Zug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla® (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMuscula® for the symptomati...
Q3FY20 result highlights During the qtr, Lupin divested Japanese, Kyowa for an EV of Rs37bn. Financials are restated for this divestment. Restated revs declined 3.5% yoy; and declined 3% qoq to Rs37.7bn. US sales came at $186mn (Q2 - $184m). We estimated base US sales of $195m but sales came substantially lower. Branded sales $4.5m for qtr. India grew 9% yoy largely inline with IPM, but below est of 12% yoy . Restated EBITDA stood at Rs4.3bn (-33% qoq) lower than est, due to higher other ex...
Lupin: Weak 3QFY20; Revival in US sales/cost reduction remains key (LPC IN, Mkt Cap USD4.6b, CMP INR721, TP INR840, 17% Upside, Buy) Strategy of complex product portfolio for US market continues LPC is focused on building a niche pipeline for the US market and in process to resolve regulatory issues at its manufacturing sites. LPC intends to grow in the branded domestic formulation (DF) segment by (a) introducing new products, and (b) increasing reach. 3QFY20 EBITDA margins are lowest in...
Event Lupin has entered into an agreement to divest its Japanese subsidiary, Kyowa to Unison for an EV of Rs37bn. Key highlights Lupin has entered into an agreement to divest its Japanese subsidiary, Kyowa Pharmaceutical to a PE fund Unison for an EV of JPY 57,361m (Rs37bn; $530m). The divested business recorded sales of JPY 14,241m in H1FY20 (~11-12% of FY20E consolidated sales). Mgt indicated EBITAM were 15-18%. ~15% EBITDA margin implies a valuation of ~13.5x EV / EBITDA. Overall, give...
Lupin: Announces sale of Kyowa biz; Deal to improve financial leverage, boost inorganic prospects (LPC IN, Mkt Cap USD4.7b, CMP INR736, TP INR860, 17% Upside, Buy) Lupin (LPC) has announced the sale of its entire stake in Kyowa Pharma to Unison, subject to customary closing conditions, including approval by the company’s shareholders. The stake will be sold at an enterprise value (EV) of INR37b, which implies EV/sales of 2x. This, in our view, is fair valuation, given the adverse pricin...
Q2FY20 result highlights Lupin’s adj. revenues declined 5% qoq; up 7.4% yoy to Rs41.2bn vs est of Rs43.4bn. US sales came at $184mn (Q1 - $218m). We estimated base US sales of $200m ex-gRanexa but sales came substantially lower; indicative of a smaller recurring biz. Branded sales $5m for qtr. India grew 12% yoy largely inline with IPM. EBITDA stood at Rs7.3bn (-1% qoq) vs est of Rs8bn aided by Rs1.4bn licensing income, primarily due to lower revs and lower GMs. Adj for one-time licensing in...
LUPIN: Subdued near-term outlook; Potential approval remains key (LPC IN, Mkt Cap USD4.9b, CMP INR759, TP INR875, 15% Upside, Buy) DF drives overall revenue growth: 2QFY20 revenues were up 10% YoY at INR43.5b (in-line), largely led by Domestic formulation (DF, 31% of sales). DF sales grew 11.5% YoY to INR13.4b. US sales increased 8% YoY to USD184m (31% of sales) while EMEA sales grew 8.3% YoY to INR3.2b (8% of sales). Overall growth was offset to some extent due to muted APAC (15% of sales) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.